Boehringer to invest EUR 120 million to expand production site in Greece for new medicine

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications, some of them in the late-stage development of the company’s strong innovation pipeline. Main disease areas include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis.

The expansion will create 110 additional jobs and boost medicine exports from Greece, particularly of Jardiance, a medication used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease, to the US market.

Greek Prime Minister Kyriakos Mitsotakis attended the groundbreaking ceremony at the Koropi site on January 11, alongside the Minister of State, the Minister of Health and the Minister of Development. He said: “I am delighted to once again visit this plant which, as we have heard, produces some of the most innovative antidiabetic medicines, and to see the excellent organization as well as the high level of expertise and professionalism of the staff. I am also very pleased with the progress that the company has made; with the 700 skilled employees whose number will increase by more than 100 when this investment is completed; and, of course, with this important shift towards innovation. I want to thank the company for its continuous trust in Greece. But first and foremost, the company trusts you, the employees, not just the government or the wider environment. All together you constitute a team, building a better tomorrow, a structure with very strong foundations and that is what we are celebrating here today. You showcase the great importance we associate with the creation of value through innovation. It is a strategic goal that we as a state also embrace: to make our country a reference point for the pharmaceutical industry.”

Putting innovative production technologies in place to support successful research & development (R&D) is a key investment driver at Boehringer. In 2022, the company’s global expenditure in Human Pharma R&D amounted to EUR 4.6 billion. 25% of Human Pharma net sales are reinvested to advance science and cutting-edge research to find new therapies and treatments for patients who are waiting for new solutions in areas of high unmet patient needs. More than half of its 53,000 workforce and over 60% of R&D budgets are invested in Europe.

“We have been present in Greece since 1966, and have gradually expanded our operations in the country,” said Hubertus von Baumbach, chairman of the board of managing directors at Boehringer Ingelheim. “This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally.”

Boehringer started the production facility in Koropi in 1975. In 2020, the company announced multi-year investments to expand the site and its production capacity. The Koropi plant is the only industrial facility of a multinational pharmaceutical company in Greece producing innovative medicines.

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!